Guselkumab has received approval for moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy.1 ...

Complete clearance lasts for a very long time due to knockout of resident memory T cells within the skin,’ said the study’s ...

Dec 18 () - Japan's Takeda Pharmaceutical said on Thursday its experimental pill for a type of skin disease, developed using ...

Growth and income investors can buy these five top dividend stocks now, tomorrow, next week, or next year and hold for the ...

AbbVie to present data from multiple studies of Rinvoq, Humira & Skyrizi at the 2019 ACR/ARP) meeting: North Chicago, Illionis Tuesday, November 5, 2019, 16:00 Hrs [IST] AbbVie, a ...

In a combined network meta-analysis, infliximab and adalimumab had the greatest risk for serious infection in patients with plaque psoriasis.

Sun Pharmaceutical Industries on Monday said it has launched its global innovative drug ILUMYA in India for the treatment of moderate-to-severe plaque psoriasis. A novel biologic treatment, ILUMYA ...

Oral roflumilast showed potential as a nonbiologic systemic therapy for moderate to severe psoriasis, offering an alternative ...

Today, Takeda announced positive topline results from 2 pivotal phase 3 trials of zasocitinib (TAK-279; Takeda), demonstrating superiority over placebo across key efficacy end points in adults with ...

A real-world analysis reveals that tildrakizumab is highly effective and safe in patients with moderate-to-severe plaque ...

Takeda (TAK) stock spikes as the company announces success in two Phase 3 trials designed to evaluate its oral plaque psoriasis drug, zasocitinib. Read more here.